Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000326
Status:
WITHDRAWN
Last Update Posted:
2017-05-04
First Post:
1999-09-20
Brief Title:
BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment 1 - 1
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Study Overview
Official Title:
BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment 11
Status:
WITHDRAWN
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the clinical efficacy of the buprenorphinenaloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen
Detailed Description:
Alternate-day dosing with the 8mg buprenorphine-naloxone tablet is as safe and effective as daily dosing Outcomes are improved when the total weekly dose provided during alternate-day dosing is equal to that given during daily dosing
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01-11160-1 | US NIH GrantContract | None | httpsreporternihgovquickSearch1R01DA011160 |
| 1R01DA011160 | NIH | None | None |